Feb 25, 2025
Alzheimer’s disease is more than just memory loss—it’s a progressive neurodegenerative disorder that slowly erodes cognition, behavior, and independence. What may begin as occasional forgetfulness or difficulty recalling names can soon escalate into disorientation, personality changes, and an inability to carry out...
Read More...
Mar 05, 2024
Acoramidis Joins Bayer's Robust Lineup, Boosting Cardiology Solutions Bayer has obtained the exclusive rights to market acoramidis in Europe from Eidos Therapeutics Inc., BridgeBio International GmbH, and BridgeBio Europe B.V. Acoramidis, a highly potent and selective small molecule given orally, functions as a ...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper